Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2019-05-21 Regulatory Filings
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Oslo Børs - Received application for listing - Ultimovacs ASA
Regulatory Filings Classification · 95% confidence The document text is very short (630 characters) and announces that the Oslo Børs has received an application for listing from Ultimovacs ASA. This is a regulatory announcement concerning the company's stock market status (listing process) rather than a comprehensive financial report (like 10-K or IR) or a specific insider transaction (DIRS). Since it is a general regulatory announcement about a corporate action (listing application) that doesn't fit perfectly into the other specific categories (like CAP for financing or DLST for delisting), the most appropriate general category is Regulatory Filings (RNS).
2019-05-21 English
Ultimovacs ASA – Approval and publication of the prospectus and commencement of the bookbuilding and the application period
Capital/Financing Update Classification · 98% confidence The document explicitly announces the 'Approval and publication of the prospectus and commencement of the bookbuilding and the application period' for an Initial Public Offering (IPO). It details the offering price, the number of shares, the bookbuilding period, and the application period. This activity—raising capital through a public offering and issuing a prospectus—falls under financing activities. While it mentions the publication of a prospectus, the core event being announced is the capital raising itself. This aligns best with the 'Capital/Financing Update' category (CAP). It is not the full 10-K, an earnings release, or a general regulatory filing (RNS), as it describes a specific, major capital event.
2019-05-21 English
Ultimovacs ASA – Underwritten initial public offering on the Oslo Stock Exchange
Capital/Financing Update Classification · 99% confidence The document explicitly announces the terms of an 'Underwritten initial public offering (the "IPO")' for Ultimovacs ASA on the Oslo Stock Exchange. It details the offer price, the number of shares being offered, the intended use of proceeds, the underwriting syndicate, and the expected listing timeline. This content is characteristic of a primary capital raising event, specifically an Initial Public Offering, which falls under the category of Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory announcement (RNS), as it focuses specifically on the mechanics and terms of the share issuance.
2019-05-20 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.